RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I study

Gerald F. Watts, Dick C. Chan

Open source

DOI
10.1002/ctm2.1484
Published
2023-11
Container
Clinical and Translational Medicine
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/ctm2.1484,
  title = {RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I study},
  author = {Gerald F. Watts and Dick C. Chan},
  year = {2023},
  journal = {Clinical and Translational Medicine},
  doi = {10.1002/ctm2.1484},
  url = {https://doi.org/10.1002/ctm2.1484}
}

RIS

TY  - JOUR
TI  - RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I study
AU  - Gerald F. Watts
AU  - Dick C. Chan
PY  - 2023
JO  - Clinical and Translational Medicine
DO  - 10.1002/ctm2.1484
UR  - https://doi.org/10.1002/ctm2.1484
ER  - 

APA

Watts, G. F., & Chan, D. C. (2023). RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I study. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1484

Source records